DMD # 67397 Introduction
Lorcaserin hydrochloride hemihydrate*, a selective serotonin 5-HT 2C receptor agonist, is approved by the US FDA for chronic weight management. It is a secondary aminecontaining benzazepine, [(R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine] (Fig.1) . Lorcaserin is primarily cleared by metabolism. Multiple metabolic pathways such as oxidation, glucuronide conjugation, and sulfo-conjugation have been identified both in vitro and in vivo. Multiple cytochrome P450 (CYPs) (Usmani et al., 2012) and UDPglucuronosyltransferase (UGTs) (Sadeque et al., 2012) enzymes associated with major metabolic pathways of lorcaserin have been reported; however, the sulfotransferases DMD # 67397 8 Initially, the liver cytosol preparation was used to optimize the reaction conditions using para-nitrophenol, a probe substrate commonly used to measure sulfotransferase activity, according to the method described previously (Gamage et al., 2003) . Following initial optimization, the incubation conducted for lorcaserin N-sulfamate formation for each enzyme system used is described below.
Enzyme Kinetics Assays for Lorcaserin N-sulfamate Formation with Cytosol:
The incubation mixtures (500 μ L final volume) consisted of human liver or renal cytosol (1 mg/mL), tris-HCl buffer (100 mM, pH 7.4), and an appropriate concentration of lorcaserin (0-10 mM as appropriate). The reaction mixture was pre-incubated at 37 o C in a shaking water bath for 3 min, and then the reaction was initiated by the addition of PAPS (100 µM). Incubations were continued for 25 min, and then terminated by the addition of 500 μ L of acetonitrile. All incubations were performed in triplicate. Incubation with para-nitrophenol was conducted as a positive substrate control. Incubations without the addition of PAPS were also conducted as a negative control under identical conditions to rule out the possible involvement of non-enzymatic process.
Assay for Lorcaserin N-sulfamate Formation with Human Recombinant
Sulfotransferase: Incubations were carried out as described below with final reagent concentrations given in parentheses. The incubation mixtures consisted of tris-HCl buffer (100 mM, pH 7.5), PAPS (100 µM) and lorcaserin (0-10 mM as appropriate depending of SULT used). The incubation mixture was pre-incubated at 37 o C in a shaking water bath for 3 minutes, and then the reaction was initiated by the addition of human recombinant SULTs enzymes (15-20 µg protein/mL) bringing the final volume to Enzymatic Assay Sample Processing: After termination of the incubation with an equal volume of acetonitrile, samples were vortexed and centrifuged for 10 min at 13,000 rpm in a microcentrifuge. The supernatant was transferred to a clean 96-well microtiter plate and subjected to LC/MS/MS analysis.
Assay for CYP Enzyme Induction by Lorcaserin N-sulfamate in Human Hepatocytes:
Lorcaserin N-sulfamate (0.2, 2, and 20 μ M) and known CYP inducers, 3-methylcholanthrene, phenobarbital, and rifampicin, were incubated in cultures of human hepatocytes from three separate donors (2 male and 1 female) for 3 consecutive days.
Cells were harvested and microsomes were prepared (LeCluyse, 2000) . The activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4 were determined using CYPselective marker substrates (described in the previous section). Messenger RNA levels for each of these CYP isozymes were analyzed by quantitative RT-PCR (TaqMan®). and CYP3A4-mediated midazolam 1′-hydroxylase was >100 μM (Fig. 6 ). However, the IC 50 value for CYP2C9-mediated tolbutamide 4′-hydroxylase was 10.3 μM (2840 ng/mL) ( Table 2 ). As shown in Table 2 , in the presence of increasing concentrations of human serum albumin in microsomal incubations, the IC 50 value for CYP2C9 inhibition was increased such that at a physiologically relevant albumin concentration of 500 µM, the IC 50 value observed for CYP2C9 inhibition was >200 μM (Fig. 7) . There was no induction observed for major CYP enzymes when cultured human hepatocytes were treated with lorcaserin N-sulfamate (up to 20 µM) for 72 hours, suggesting that lorcaserin N-sulfamate is not a human CYP enzyme inducer (data not shown). Table   3 .
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DISCUSSION
Sulfo-conjugates of xenobiotics and endobiotics are generally biologically inactive and hydrophilic, therefore represents a biologically important excretion pathway (Coughtrie, 2002; Strott, 2002; Stillwell et al., 1994; Glatt, 2005) . However, the structural features of certain sulfo-conjugated molecules may elicit various biological effects. For example, the O-sulfo-conjugates of aromatic hydroxylamines, benzylic and allylic alcohols are known to be short-lived and electrophilic, and may therefore bind to cellular nucleophiles, including DNA (DeBaun et al., 1970; Glatt, 2005) . In addition, some sulfoconjugates show biological activity, such as cholesterol sulfate, known to stimulate differentiation of skin epidermal cells (Elias et al., 1984) , and pregnenolone sulfate, which binds and suppresses the GABA receptor (Corpéchot et al., 1981) . However, sulfo-conjugation via N-sulfation, such as N-sulfonation of aromatic amines, yields stable sulfo-conjugates which are readily excreted without toxicological consequences (Stillwell et al., 1994; Glatt, 2005) . In this report, we describe the formation and systematic characterization of lorcaserin N-sulfamate, formed by human liver or renal cytosol and recombinant sulfotransferases. The lorcaserin sulfo-conjugate is not the product of O-sulfonation, but rather N-sulfonation, and is known to be chemically stable (Stillwell et al., 1994; Glatt, 2005) . Thus, toxicological consequences of lorcaserin Nsulfamate are considered to be unlikely.
Prior to the characterization of lorcaserin N-sulfamate formation kinetics, the sulfotransferase activity of the cytosolic preparations was verified using paranitrophenol, a known substrate for SULTs. Typical biphasic kinetics with initial product formation (para-nitrophenol -sulfate) at low p-nitrophenol concentration followed by
at ASPET Journals on July 6, 2017 dmd.aspetjournals.org Downloaded from inhibition of its own product formation at higher concentration was observed (data not shown) as reported previously (Gamage et al., 2003) . The kinetic parameters for lorcaserin N-sulfamate formation showed that the V max and CL int values for liver cytosol are about 17-and 15-fold higher, respectively, than that for renal cytosol.
suggesting that lorcaserin N-sulfamate is predominantly formed by liver SULTs. An initial screening with recombinant SULTs indicated that SULT1A1, SULT1A2, SULT1E1, and SULT2A1 were involved in lorcaserin N-sulfamate formation whereas SULT1A3
showed minimal or no activity (Fig. 4) . The intrinsic clearance value of SULT1A1 is about 89-, 13-, and 137-fold higher compared to SULT1A2, SULT2A1 and SULT1E1, respectively, suggesting that SULT1A1 is the predominant SULT that catalyzes lorcaserin N-sulfamate formation in humans (Table 1) hydrophobic chloro-benzene moiety of lorcaserin likely makes it a poor substrate for SULT1A2. Like SUL1A2, SULT2A1 also showed low affinity for lorcaserin N-sulfamate formation. The active site of SULT2A1 appears to accept more hydrophobic substrates such as steroids, steroid derivates and bile acids (Comer et al., 1993; Huang et al., 2010) . Additionally, specific binding orientation in SULT2A1 is required for specific substrates such as dehydroepiandrosterone and androsterone (Lu et al., 2008) . This may be the reason why lorcaserin is not a high affinity substrate for SULT2A1.
Comparing all the SULTs used for lorcaserin N-sulfamate formation, SULT1A1 appears to be the most catalytically efficient. Based on intrinsic clearance values, the order of catalytic efficiency is SULT1A1>SULT2A1>SULT1A2>SULT1E1. As indicated by the kinetic parameters, lorcaserin does not appear to be a prototypical high affinity substrate for human SULT enzymes. Thus, drug-drug interactions arising through the sulfotransferase-mediated metabolic pathway are not anticipated. Additionally, though lorcaserin N-sulfamate is the major metabolite in circulation, it accounts only approximately 3% of total lorcaserin dose in human urine, whereas the major clearance pathways of lorcaserin are oxidation by multiple CYP enzymes (Usmani et al., 2012) and glucuronidation by multiple UGT enzymes (Sadeque et al., 2012) . The observed pharmacokinetic half-life of lorcaserin N-sulfamate after lorcaserin dosing in human is much longer than the parent (~40 hr vs ~11 hr). One likely explanation for the high levels of lorcaserin N-sulfamate in circulation and prolonged observed half-life is that its very high plasma protein binding affinity (>99%) renders only a small free fraction of the metabolite in circulation available for tissue distrubition and elimination. We also observed that lorcaserin N-sulfamate inhibits human liver microsomal tolbutamide hydroxylation with an IC 50 of ~10 µM, a reaction catalyzed by CYP2C9. However, the IC 50 value becomes >200 µM in the presence of physiological concentration of human serum albumin (Fig.7) . Additionally, lorcaserin N-sulfamate has no or minimal inhibitory effect on other major CYP enzymes (Fig. 6) and also is not a time dependent inhibitor of CYP 2C9 (data not shown). On the other hand, although the parent drug, lorcaserin, inhibits CYP 2D6 activity (approximately 2-fold increase in AUC of dextromethorphan, see prescribing information for reference), it is also not a time dependent inhibitor of CYP2D6. In a separate experiment we found that only 10% of lorcaserin N-sulfamate is bound to microsomal protein, in contrast to >99% bound to human plasma protein.
Thus, in an in vivo environment, the availability of free lorcaserin N-sulfamate in circulation would be very negligible at a clinical dose of lorcaserin and is highly unlikely to cause metabolic inhibition of the CYP2C9 pathway. In this study, we have demonstrated that lorcaserin undergoes N-sulfation, thus forming a chemically stable sulfo-conjugate and an excretory pathway (Glatt, 2005) . We also demonstrated that although lorcaserin N-sulfo-conjugation is catalyzed by multiple SULTs, lorcaserin does not appear to be a high-affinity substrate for these enzymes.
Lorcaserin N-sulfamate is a minor clearance pathway in humans as it accouts for only This article has not been copyedited and formatted. The final version may differ from this version. 3% of lorcaserin dose in urine. Further, its high plasma protein binding affinity (>99%) is consistent with its long half life in circulation. Importantly, it is neither a clinicallyrelevant CYP enzyme inhibitor nor inducer. In conclusion, lorcaserin N-sulfamate has a very low probability of causing metabolic drug-drug interactions in a normal patient population.
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